Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2026-02-06 00:00:00 ET · period of report 2026-02-04 · accession 0001859453-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-06 | 2026-02-04 | VERA | Fordyce Marshall | Pres AND CEO, Dir | A - Grant | $0.00 | +68.8K | 274.1K | +34% | $0 |
| D | 2026-02-06 | 2026-02-04 | VERA | Fordyce Marshall | Pres AND CEO, Dir | A - Grant | $0.00 | +137.5K | 137.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-04 | A | A | 68,800 | $0.00 | 274,088 | D | — | — | (F1) Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. (F2) Includes 623 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025. |
| 2 | Derivative | Stock Option (right to buy) | 2026-02-04 | A | A | 137,500 | $0.00 | 137,500 | D | $42.74 · — to 2036-02-03 | 137,500 Class A Common Stock | (F4) 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |